Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.50
Bid: 47.50
Ask: 47.80
Change: 0.60 (1.28%)
Spread: 0.30 (0.632%)
Open: 47.40
High: 47.50
Low: 45.45
Prev. Close: 46.90
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Modern Water plc

1 Sep 2020 17:18

RNS Number : 7314X
IP Group PLC
01 September 2020
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

IP Group plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Modern Water plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

31/08/20

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

15,901,053

3.03

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

15,901,053

3.03

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

None

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

None

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

None

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

None

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

None

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

01/09/20

Contact name:

Greg Smith

Telephone number*:

0207 444 0050

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETEAKNFEFXEEFA
Date   Source Headline
8th Oct 20187:07 amRNSPortfolio co Diurnal headline data for Chronocort
19th Sep 20189:51 amRNSDirector/PDMR Shareholding
17th Sep 20184:58 pmRNSDirector/PDMR Shareholding
17th Sep 20184:38 pmRNSDirector/PDMR Shareholding
17th Sep 201812:12 pmRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSAppointment of Chairman; Board changes
31st Aug 20189:55 amRNSHolding(s) in Company
30th Aug 20187:00 amRNSGenomics announces Vertex leads £25m financing
29th Aug 20186:29 pmRNSIP Group plc -SAYE scheme
21st Aug 20187:06 amRNSCeres signs agreement with Bosch; £9m investment
10th Aug 20187:11 amRNSArtios Pharma completes £65m financing
31st Jul 20188:40 amRNSTR-1: NOTIFICATION
25th Jul 20187:00 amRNSHalf-yearly results
6th Jul 20187:00 amRNSNotification of Major Interest in Shares
4th Jul 20182:40 pmRNSCeres Power announces £20m fundraising
2nd Jul 20187:00 amRNSHolding(s) in Company
27th Jun 20187:30 amRNSCarisma announces $53m Series A funding round
27th Jun 20187:00 amRNSNotification of Major Interest in Shares
22nd Jun 201810:00 amRNSAppointment of Joint Broker
18th Jun 20181:37 pmRNSResult of AGM
7th Jun 20186:00 pmRNSHolding(s) in Company
6th Jun 20189:26 amRNSMicrobiotica signs collaboration worth up to $534m
16th May 201810:49 amRNSPortfolio co Ceres partners with Weichai Power
16th May 20187:00 amRNSNotice of AGM; Annual Report
11th May 20187:00 amRNSDirector/PDMR Shareholding
10th May 20186:18 pmRNSDirector/PDMR Shareholding
9th May 20185:31 pmRNSDirector share purchase
4th May 20187:00 amRNSBoard changes
30th Apr 20187:00 amRNSTotal Voting Rights
16th Apr 20185:45 pmRNSDirector/PDMR Shareholding
12th Apr 20189:19 amRNSEnterprise Therapeutics raises £29m
5th Apr 20181:12 pmRNSIP Group plc - Issue of Equity
4th Apr 201811:46 amRNSIP Group plc - Director/PDMR share purchase
29th Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSOxford Nanopore announces £100m fundraising
17th Jan 201811:53 amRNSHolding(s) in Company
10th Jan 20189:12 amRNSHolding(s) in Company
2nd Jan 20187:00 amRNSTotal Voting Rights
18th Dec 201710:15 amRNSAutifony signs Eur627.5m agreement with BI
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
14th Dec 20174:48 pmRNSDirectorate Change
13th Dec 20172:27 pmRNSIssue of Equity
8th Dec 20177:05 amRNSMirriad raises £26.2m; proposed admission to AIM
6th Dec 20172:32 pmRNSIssue of Equity
30th Nov 201712:40 pmRNSTotal Voting Rights
27th Nov 20176:27 pmRNSIssue of Equity
22nd Nov 20175:50 pmRNSHolding(s) in Company
22nd Nov 20173:23 pmRNSIssue of Equity
15th Nov 201712:47 pmRNSIssue of Equity
14th Nov 201712:29 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.